Pharmacokinetics and safety of subcutaneous nivolumab: results from the phase I/II CheckMate 8KX study
Background CheckMate 8KX was a phase I/II study investigating the pharmacokinetics and safety of subcutaneous (SC) nivolumab±recombinant human hyaluronidase PH20 (rHuPH20).Methods Patients with advanced solid tumors who were immune-checkpoint inhibitor-naïve were included. In parts A and B, patients...
Na minha lista:
| Principais autores: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BMJ Publishing Group
2025-10-01
|
| 叢編: | Journal for ImmunoTherapy of Cancer |
| 在線閱讀: | https://jitc.bmj.com/content/13/10/e011918.full |
| 標簽: |
沒有標簽, 成為第一個標記此記錄!
|
